期刊文献+

一例多发性骨髓瘤治疗相关性骨髓增生异常综合征 被引量:9

原文传递
导出
摘要 随着放/化疗在肿瘤治疗中成功应用,作为治疗远期并发症之一的治疗相关性骨髓增生异常综合征(treat-related myelodysplastic syndromes,t-MDS)的患者逐渐增多。迄今文献报道的多发性骨髓瘤(multiple myeloma,MM)t-MDS(MM-t-MDS)有80余例^[1-5]。最近我们诊治了1例MM-t-MDS,现报告如下。
出处 《中华血液学杂志》 CAS CSCD 北大核心 2008年第4期270-271,共2页 Chinese Journal of Hematology
基金 国家自然科学基金(30670899) 高等学校博士学科点专项科研基金(20050023033)
  • 相关文献

参考文献6

  • 1Amiel A, Yukla M, Yogev S, et al. Deletion of 5q31 and 7q31 in patients with stable melphalan-treated multiple myeloma. Cancer Genet Cytogenet, 2004, 152 : 84-87.
  • 2Ishii Y, Hsiaoa HH, Sashidaa G, et al. Derivative (1;7)(q10; p10) in multiple myeloma. A sign of therapy-related hidden myelodysplastic syndrome. Cancer Genet Cytogenet, 2006, 167: 131- 137.
  • 3Mauritzson N, Albin M, Rylander L, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia, 2002, 16: 2366-2378.
  • 4Rodjer S, Swolin B, Weinfeld A, et al. Cytogenetic abnormalities in acute leukemia complicating melphalan-treated multiple myeloma. Cancer Genet Cytogenet, 1990, 48 : 67-73.
  • 5Nilsson T, Nilsson L, Lenhoff S, et al. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance : evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q). Genes Chromosomes Cancer, 2004, 41 : 223-231.
  • 6肖志坚.骨髓增生异常综合征的诊断和治疗认识现况[J].国际输血及血液学杂志,2007,30(1):1-4. 被引量:9

二级参考文献23

  • 1肖志坚,郝玉书.儿童骨髓增生异常综合征的诊断分型[J].中华儿科杂志,2005,43(7):545-547. 被引量:7
  • 2肖志坚.重视和加强我国儿童骨髓增生异常综合征的研究[J].中国小儿血液,2005,10(3):97-98. 被引量:6
  • 3肖志坚.骨髓增生异常综合征:现况与问题[J].白血病.淋巴瘤,2005,14(4):193-196. 被引量:31
  • 4Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood,2002, 100(7) :2292-2302.
  • 5Catenacci DVT, Schiller GJ. Myelodysplasic syndromes: A comprehensive review. Blood Rev, 2005, 19(6) :301-319.
  • 6Fukumotoa JS, Greenberg PL. Management of patients with higher risk myelodysplastic syndromes. Cri Rev Oncol/Hematol, 2005, 56(2):179-192.
  • 7Steensma DP, Tefferi A. The myelodysplastic syndrome (s): a perspective and review highlighting current controversies. Leuk Res, 2003,27(9) :95-120.
  • 8Greenberg P, Cox C, Le Beau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997, 89(6) :2079-2088.
  • 9Greenherg PL. Myelodysplastic Syndromes: Iron Overload Consequences and Current Chelating Therapies. J Natl Compr Cancer Netw, 2006,4(1) :91-96.
  • 10Hellstom-Lindberg E, Guldbrandsen N, Lindberg Get al. A validated decision model for treating MDS with erythropoietin and GCSF : Significant effects on quality of life. Br J Haematol, 2003,120(6) : 1037-1046.

共引文献8

同被引文献78

引证文献9

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部